Outcomes of coronary revascularization in patients with metabolic dysfunction-associated steatotic liver disease: a systematic review
IntroductionA growing amount of evidence suggests that metabolic dysfunction-associated steatotic liver disease (MASLD) may independently increase the risk of coronary artery disease and acute coronary syndrome, thus necessitating revascularization interventions such as percutaneous coronary interve...
Saved in:
| Main Authors: | Jacob J. Gries, Hafeez Ul Hassan Virk, Zhen Wang, Mahboob Alam, Samin Sharma, Markus Strauss, Chayakrit Krittanawong |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2025.1609071/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
MAFLD or MASLD: Which better represents the prognosis of the steatotic liver population: Letter to the editor on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
by: Ying Wang, et al.
Published: (2025-04-01) -
Applicability of Statins in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
by: Thaninee Prasoppokakorn
Published: (2025-01-01) -
Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease
by: Yue Wang, et al.
Published: (2025-02-01) -
Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023
by: Donghee Kim, et al.
Published: (2025-04-01) -
<i>Lactobacillus</i> sp. for the Attenuation of Metabolic Dysfunction-Associated Steatotic Liver Disease in Mice
by: Titilayo Olotu, et al.
Published: (2024-12-01)